US Patent 6,855,339: Arsenic Trioxide Treatment Regimen, Claim Scope, Expiration, and Patent Landscape

US Patent 6,855,339 protects a method-of-treatment regimen for acute promyelocytic leukemia using arsenic trioxide at approximately 0.15 mg/kg per day. Its core protection covers induction treatment for up to 60 days or until bone marrow remission, followed by 25-dose consolidation courses administered at defined intervals. The patent is no longer an active barrier to generic arsenic trioxide products because its statutory term ended in 2021. The claims remain relevant for historical Orange Book analysis, infringement review, and the development of later APL treatment patents.

What does US Patent 6,855,339 cover?

US Patent 6,855,339 covers the use of arsenic trioxide to treat acute promyelocytic leukemia, or APL, according to a specified induction and consolidation schedule.

The patent has two independent claims:

Claim	Independent subject matter	Principal limitation
1	Weight-based method of treating APL	Approximately 0.15 mg/kg, administered for up to 60 days or until bone marrow remission
11	Human treatment method	Approximately 0.15 mg/kg once daily for up to 60 days or until bone marrow remission

Claims 2 through 10 depend from claim 1. Claims 12 through 20 depend from claim 11. The two claim groups are substantially parallel.

The claimed regimen contains five principal elements:

The disease must be acute promyelocytic leukemia.
The active agent must be arsenic trioxide.
The dose must be approximately 0.15 mg/kg.
The first administration must continue for up to 60 days or until bone marrow remission.
A subsequent administration may consist of 25 doses, typically five doses per week for up to five weeks, beginning three to six weeks after the first administration.

The dependent claims extend protection to repeated consolidation courses. They cover two through ten total consolidation cycles, including specifically two cycles and ten cycles.

What are the key limitations in claims 1 and 11?

Claims 1 and 11 are similar but have different drafting requirements.

Claim 1: weight-based dose determination

Claim 1 requires determining the dosage amount based on the patient's body weight and administering approximately 0.15 mg/kg. The claim is directed to a dosing calculation and treatment act.

A literal infringement theory would generally require evidence that:

The patient had APL.
The treating party determined the arsenic trioxide dose using patient weight.
The administered dose was approximately 0.15 mg/kg.
The treatment was conducted for no more than 60 days or until bone marrow remission.
The administration was the first administration within the claimed treatment sequence.

The phrase "about 0.15 mg/kg" introduces a numerical range rather than an exact 0.15 mg/kg requirement. The patent specification and prosecution history would be relevant to determining the permissible range. The claim does not state a precise percentage tolerance.

Claim 11: once-daily human treatment

Claim 11 does not expressly require a separate determination of dose based on body weight. It requires administration to a human of approximately 0.15 mg/kg once per day.

This creates a potentially broader practical claim than claim 1 in one respect: a treatment protocol could fall within claim 11 even if the prescribing record does not expressly document a weight-based calculation, provided the actual administered dose and daily schedule meet the claim limitations.

Both claims require the treatment to be a "first administration." That language ties the independent claims to the induction phase and distinguishes the later consolidation administration recited in the dependent claims.

What formulations and treatment schedules are protected?

The patent primarily protects a clinical dosing regimen, not a particular injectable formulation, excipient system, container, or manufacturing process.

Induction phase

The independent claims cover:

Parameter	Claimed requirement
Disease	Acute promyelocytic leukemia
Patient	Human patient under claim 11; patient diagnosed with APL under claim 1
Drug	Arsenic trioxide
Dose	Approximately 0.15 mg/kg
Frequency	Once per day under claim 11; weight-based administration under claim 1
Duration	Maximum of 60 days or until bone marrow remission
Treatment phase	First administration

The claim does not require a particular intravenous infusion time, concentration, vial size, diluent, route language beyond administration, or combination with all-trans retinoic acid, commonly called ATRA.

Consolidation phase

The dependent claims cover a second administration consisting of:

Approximately 0.15 mg/kg per dose.
Twenty-five total doses.
Administration three to six weeks after the first administration.
Up to five weeks of treatment.
Five doses per week.
Repetition every three to six weeks.
Two to ten total consolidation cycles.

The regimen resembles the clinical schedule used for Trisenox treatment of APL. The current FDA labeling for arsenic trioxide describes induction dosing at 0.15 mg/kg daily until bone marrow remission or for a maximum of 60 doses, followed by consolidation dosing at 0.15 mg/kg daily for 25 doses over up to five weeks after a rest period [2]. The patent and label use closely related dosing concepts, although the legal scope of the patent depends on the exact claim language and the applicable label version.

When did US Patent 6,855,339 expire?

US Patent 6,855,339 issued on February 15, 2005. Its statutory patent term expired in 2021, based on the applicable US patent-term calculation. The patent therefore does not currently provide an enforceable exclusionary right against generic arsenic trioxide treatment protocols.

Event	Date or status
Patent issued	February 15, 2005
Patent type	Utility patent
Protection type	Method of treating APL
Statutory term	Ended in 2021
Current blocking status	Expired
Current generic risk	No live exclusion based solely on this patent

The relevant expiration date should be taken from the USPTO patent-term record for final legal determinations, including any patent-term adjustment. No patent-term extension appears to preserve an active right under this treatment patent.

What was the Orange Book status of US Patent 6,855,339?

US Patent 6,855,339 was historically associated with the arsenic trioxide product Trisenox. The patent covered the clinical use of arsenic trioxide in APL rather than the chemical identity of arsenic trioxide itself.

The FDA Orange Book distinguishes between:

Drug substance patents.
Drug product or formulation patents.
Method-of-use patents.

A patent directed to an APL treatment regimen may be listed with a use code tied to the approved indication. Such a listing can require a generic applicant to make a certification under the Hatch-Waxman framework if the patent is listed for the reference product.

The listing does not extend the patent term, create a new exclusivity period, or prevent approval after expiration. Once the patent expired, the listing ceased to create a current patent-based launch barrier.

The product's historical regulatory framework included:

FDA approval of Trisenox for relapsed or refractory APL.
Orphan-drug exclusivity associated with the initial APL approval.
Later expansion of the label to newly diagnosed low- or intermediate-risk APL in combination with ATRA.
Generic arsenic trioxide injection approvals after the relevant patent and exclusivity periods.

Orphan-drug exclusivity is separate from patent protection. It protects the approved orphan indication for a defined period but does not prevent approval of the same drug for a different indication or eliminate later generic competition after the exclusivity period ends [1, 3].

How strong is the patent estate for arsenic trioxide and APL?

The patent estate was commercially important during the period when Trisenox had regulatory and market exclusivity. It is now historically significant rather than commercially blocking.

Strengths of US Patent 6,855,339

The patent had several practical advantages:

It claimed the central clinical regimen used for APL.
It included both a weight-based formulation and a once-daily human-treatment formulation.
It covered induction and consolidation phases.
It captured repeated consolidation cycles.
It aligned closely with the clinical use reflected in the product label.

Limitations of the patent

The patent also had meaningful limitations:

It was limited to APL rather than all hematologic cancers.
It required a specific approximate dose.
It required timing and duration limitations.
It did not claim arsenic trioxide as a chemical compound.
It did not necessarily cover every dose, schedule, route, or combination regimen.
It did not prevent manufacture of arsenic trioxide for non-APL uses.
It expired in 2021.

The claims are treatment-method claims. They are not composition-of-matter claims, manufacturing claims, or broad formulation claims.

What Paragraph IV challenges affected arsenic trioxide?

A Paragraph IV certification is relevant when a generic applicant seeks approval before expiration of an Orange Book-listed patent and asserts that the patent is invalid, unenforceable, or will not be infringed.

For arsenic trioxide, the commercial significance of a Paragraph IV challenge was limited by the relatively narrow method claims and the eventual expiration of the patent. A generic applicant could also pursue a section viii statement, or "skinny label," excluding the patented indication if the FDA labeling and patent listing permitted that strategy.

Potential certification positions included:

Certification position	Commercial effect
Paragraph III	Approval delayed until patent expiration
Paragraph IV	Approval may trigger patent litigation and a potential 30-month stay
Section viii	Generic label omits the patented method of use
No current patent barrier	Approval proceeds after expiration

Because the patent expired in 2021, a current applicant is not exposed to a live Paragraph IV dispute based on US Patent 6,855,339 alone. Any present litigation risk would have to arise from a different patent, regulatory issue, product-specific patent, or conduct unrelated to the expired claims.

Which companies challenged or competed with the Trisenox estate?

The principal commercial competition came from generic arsenic trioxide injection manufacturers rather than biosimilar developers.

Arsenic trioxide is a small-molecule drug. It is not a biologic, so the biosimilar pathway under the Public Health Service Act is not applicable. Competition proceeds through the abbreviated new drug application, or ANDA, pathway under the Federal Food, Drug, and Cosmetic Act.

Relevant competitive categories include:

Generic injectable arsenic trioxide manufacturers.
Trisenox and its successor commercial rights holders.
Manufacturers developing alternative APL regimens based on ATRA and arsenic trioxide.
Products using different dosage forms or administration systems.

The competitive landscape changed materially after FDA approval of generic arsenic trioxide products. Generic products could rely on the established safety and efficacy of the reference drug while avoiding any expired method patent. FDA product-specific approvals and current labeling should be reviewed for the exact manufacturer and launch date [3].

What licensing deals affected Trisenox and this patent?

The patent record establishes ownership and prosecution information, but a patent document alone does not establish the complete commercial licensing chain.

Trisenox was commercialized through a sequence of companies, including Cell Therapeutics, Cephalon, and Teva. Commercial rights, distribution rights, and patent licenses may have been transferred or sublicensed during those transactions. A corporate acquisition or product transaction does not automatically transfer every patent right in the same form; assignment records and transaction agreements control.

For diligence purposes, the relevant distinction is:

Asset	Commercial relevance
US Patent 6,855,339	Historical APL regimen protection; expired
Trisenox trademark and product rights	Separate from patent rights
FDA approval	Regulatory authorization; not patent ownership
Commercial license	Contractual rights; not established solely by the patent
Generic ANDA approval	Regulatory authorization to market a product meeting FDA requirements

What patent litigation affects US Patent 6,855,339?

The key litigation exposure was the standard Hatch-Waxman risk associated with a generic applicant certifying against a listed method-of-use patent. A Paragraph IV notice could have led to a patent infringement action under 35 U.S.C. § 271(e)(2), with a potential 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii).

The expired status of the patent changes the present analysis:

No current 30-month stay can be based on an expired patent.
No current injunction can rest on the expired claims.
Historical settlement agreements may still be relevant to launch timing but do not revive the patent.
A settlement cannot extend statutory patent rights beyond the expiration date.
Any current dispute must be tested against other patents or regulatory grounds.

No active exclusionary position should be attributed to US Patent 6,855,339 in a current generic-entry model.

How does this patent compare with formulation and manufacturing patents?

US Patent 6,855,339 is narrower in subject matter than a composition-of-matter patent but can be commercially powerful when its claims track the approved label.

Patent category	Typical protection	Relevance to arsenic trioxide
Composition of matter	New chemical entity	Weak relevance because arsenic trioxide is an old compound
Method of treatment	Dose, patient, disease, schedule	Core subject of US 6,855,339
Formulation	Concentration, excipients, stability	May affect injectable product competition
Manufacturing	Synthesis, purification, process controls	Can create production barriers
Device or container	Administration system or packaging	May affect product-specific competition
Regulatory exclusivity	FDA statutory protection	Separate from patent rights

Manufacturing and formulation patents would be evaluated independently. A generic manufacturer could avoid an expired treatment patent yet still face a live patent directed to a particular formulation, process, container, or delivery system. Conversely, a generic product that uses a different formulation may avoid those claims while practicing the same clinical regimen.

What generic launch risks exist for arsenic trioxide?

The principal generic launch risks are regulatory and commercial rather than tied to US Patent 6,855,339.

Regulatory risks

A generic applicant must demonstrate pharmaceutical equivalence, bioequivalence where applicable, product quality, sterility, stability, and compliance with FDA manufacturing requirements. Injectable products face heightened scrutiny regarding sterility, particulate matter, container closure, and manufacturing controls.

Commercial risks

Arsenic trioxide is used in a specialized hematology market. Commercial factors include:

Limited APL patient volume.
Hospital purchasing contracts.
Oncology distributor access.
Injectable manufacturing capacity.
Shortages or supply interruptions.
The need to maintain sterile production.
Competition from ATRA-based regimens.
Pricing pressure after multiple generic entrants.

Patent risks

The expired patent does not create current launch risk. A complete freedom-to-operate analysis would still review:

Later formulation patents.
Manufacturing-process patents.
Device patents.
Patent rights in non-US jurisdictions.
Contractual restrictions.
Labeling and promotional-use issues.

What is the geographic coverage of US Patent 6,855,339?

The patent provides protection only in the United States. It does not establish rights in Europe, Canada, Japan, China, or other jurisdictions.

International protection would depend on separate national patents or regional grants derived from related applications. Patent term, claim scope, opposition history, and expiration dates must be assessed country by country.

For an international launch, the US expiration does not establish that corresponding foreign rights have expired. Conversely, the existence of a foreign patent does not restore rights in the United States.

Key Takeaways

US Patent 6,855,339 covers an arsenic trioxide regimen for APL.
Its independent claims require approximately 0.15 mg/kg dosing during an induction administration.
The induction phase lasts up to 60 days or until bone marrow remission.
Dependent claims cover 25-dose consolidation courses administered three to six weeks later.
The patent covers repeated consolidation cycles ranging from two to ten cycles.
The patent is a method-of-treatment patent, not a composition-of-matter patent.
It does not broadly claim arsenic trioxide, all formulations, or all APL treatments.
The patent expired in 2021 and is not a current US generic-entry barrier.
Arsenic trioxide is a small molecule, so biosimilar analysis does not apply.
Current competition is governed primarily by FDA approval requirements, sterile injectable manufacturing, supply capacity, later patents, and market economics.
Foreign patent rights must be analyzed separately from the US patent.

FAQs

Does US Patent 6,855,339 cover arsenic trioxide for all cancers?

No. The claims are directed to treating acute promyelocytic leukemia. They do not cover every use of arsenic trioxide in oncology or other diseases.

Does the patent require arsenic trioxide to be used with ATRA?

No. The claims provided do not expressly require combination treatment with all-trans retinoic acid. ATRA combination therapy may be present in later FDA labeling or clinical practice without being a limitation of these claims.

Can a generic manufacturer market arsenic trioxide after the patent expired?

Yes, subject to FDA approval and compliance with applicable regulatory requirements. The expired patent does not prevent an approved generic manufacturer from selling arsenic trioxide.

Is a 25-dose consolidation course required in every claimed treatment?

No. Claims 1 and 11 independently cover the first administration. The 25-dose consolidation requirement appears in dependent claims 2 through 10 and 12 through 20.

Does expiration in the United States eliminate foreign patent risk?

No. US expiration eliminates the US patent barrier only. Corresponding patents in other countries may have different expiration dates, claim scope, prosecution histories, and legal status.

References

U.S. Food and Drug Administration. (2000). Trisenox (arsenic trioxide) approval history and orphan-drug information. FDA.
U.S. Food and Drug Administration. (2023). Trisenox (arsenic trioxide) injection prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Patent and Trademark Office. (2005). U.S. Patent No. 6,855,339, treatment of acute promyelocytic leukemia with arsenic trioxide. U.S. Department of Commerce.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.
35 U.S.C. § 271(e)(2) (2024).
21 U.S.C. § 355(j)(5)(B)(iii) (2024).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1397399	⤷ Start Trial
Australia	2002300339	⤷ Start Trial
Australia	747474	⤷ Start Trial
Brazil	9814857	⤷ Start Trial
Canada	2309652	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,855,339

Summary for Patent: 6,855,339